H.R. 5850 · 118th Congress · Health
To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.
What it does
The Congressional Research Service hasn’t published a summary of this bill yet. Summaries usually follow within a few weeks of introduction.
Roll call votes
No recorded roll call votes on this bill. Most bills never get one; many pass by voice vote or unanimous consent, or stay in committee.
Latest action
Oct 6, 2023 · Referred to the Subcommittee on Health.